Evidence map›Paper›PMID 32854646›Full record

Observational studyBMC cancer2020

Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.

Dieter H Heiland, Robin Ohle, Debora Cipriani, Pamela Franco, Daniel Delev, Simon P Behriger, Elias Kellner, Gergana Petrova, Nicolas Neidert, Irina Mader and 5 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Dieter H HeilandTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany. dieter.henrik.heiland@uniklinik-freiburg.de.ORCID 0000-0002-9258-3033
Robin OhleTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Debora CiprianiTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Pamela FrancoTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Daniel DelevDepartment of Neurosurgery, University of Aachen, Aachen, Germany.
Simon P BehrigerTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Elias KellnerMedical Physics, Department of Radiology, Medical Centre - University of Freiburg, Freiburg, Germany.
Gergana PetrovaTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Nicolas NeidertTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Irina MaderClinic for Neuropediatrics and Neurorehabilitation, Epilepsy Center for Children and Adolescents, Schön Klinik, Vogtareuth, Germany.
Mateo Fariña NuñezTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
Horst UrbachMedical Faculty, Freiburg University, Freiburg, Germany.
Roman SankowskiMedical Faculty, Freiburg University, Freiburg, Germany.
Jürgen BeckDepartment of Neurosurgery, Medical Center, University of Freiburg, Breisacher Straße 64, 79106, Freiburg, Germany.
Oliver SchnellTranslational NeuroOncology Research Group, Medical Center, University of Freiburg, Freiburg, Germany.
University of Freiburg · DERWTH Aachen University · DESchön Klinik Vogtareuth · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOligodendroglioma (ODG) are CNS resistant tumors characterized by their unique molecular signature, namely a combined deletion of 1p and 19q simultaneously to an IDH1/2 mutation. These tumors have a more favorable clinical outcome compared to other gliomas and a long-time survival that ranges between 10 and 20 years. However, during the course of the disease, multiple recurrences occur and the optimal treatment at each stage of the disease remains unclear. Here we report a retrospective longitudinal observation study of 836 MRI examinations in 44 ODG patients.

methodsWe quantified the volume of T2-hyperintensity to compute growth behavior in dependence of different treatment modalities, using various computational models.

resultsThe identified growth pattern revealed dynamic changes, which were found to be patient-specific an did not correlate with clinical parameter or therapeutic interventions. Further, we showed that, surgical resection is beneficial for overall survival regardless the WHO grad or timepoint of surgery. To improve overall survival, an extent of resection above 50% is required. Multiple resections do not generally improve overall survival, except a greater extent of resection than in previous surgeries was achieved.

conclusionsOur data aids to improve the interpretation of MRI images in clinical practice.

Indexed as

AdultAgedAged, 80 and overAstrocytomaBrain NeoplasmsChromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 19FemaleFollow-Up StudiesHumansIsocitrate DehydrogenaseLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseMR-imagingOligodendrogliomaSegmentation

Identifiers

PMID32854646
PMCPMC7450792
OpenAlexW3080644518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.